• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Twelve new members join DF/HCC

    Twelve individuals have recently joined DF/HCC

    Bortezomib denies leukemia stem cell development

    Acute myelogenous leukemia (AML), a disease for which treatment has remained relatively unchanged for the past 30 years, is the subject of a new clinical trial featuring a drug aimed at boosting the efficacy of standard induction chemotherapy

    Delivering a one-two punch to the PI3K signaling pathway

    Based largely on original research from a team of DF/HCC investigators, a new clinical trial has launched to determine if combination therapy with a tyrosine kinase inhibitor (neratinib) in combination with an mTOR inhibitor (temsirolimus, Torisel®) can more effectively shut down an important signaling pathway involved in solid tumors like lung and breast cancers

    Co-clinical mouse/human trials aim to speed up drug approvals

    The many breakthroughs in understanding the pathways involved in leukemia have delivered a double-edged sword: hundreds of new drugs await testing but an insufficient patient pool exists to conduct clinical testing in a timely way

    Functional genomics yields drivers, mutations, and pathways in leukemia

    The study of genes, mutations, and collective pathways contributing to leukemia is a cornerstone of the DF/HCC Leukemia Program, led by Thomas Look, MD (DFCI) and co-leaders David Scadden, MD (MGH), Pier Paolo Pandolfi, MD, PhD (BIDMC), and Scott Armstrong, MD, PhD (CHB)

    Twenty-four new members join DF/HCC

    Twenty-four individuals have recently joined DF/HCC

    BWH names Nabel next president
Displaying results 85 to 91 out of 206